NeoGenomics Inc. (NEO) Now Covered by Analysts at First Analysis
NEO has been the subject of several other reports. BTIG Research downgraded NeoGenomics from a buy rating to a neutral rating in a research report on Wednesday, July 27th. Raymond James Financial Inc. assumed coverage on NeoGenomics in a research report on Thursday, September 8th. They issued an outperform rating and a $10.00 target price for the company. Zacks Investment Research upgraded NeoGenomics from a hold rating to a buy rating and set a $9.25 target price for the company in a research report on Friday, August 5th. Benchmark Co. increased their target price on NeoGenomics from $10.00 to $12.00 and gave the company a buy rating in a research report on Wednesday, July 27th. Finally, Craig Hallum reiterated a buy rating on shares of NeoGenomics in a research report on Saturday, July 9th. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus target price of $10.41.
NeoGenomics (NASDAQ:NEO) opened at 8.075 on Monday. The company’s market cap is $628.99 million. The stock’s 50 day moving average price is $8.11 and its 200 day moving average price is $8.09. NeoGenomics has a 12-month low of $5.49 and a 12-month high of $9.54.
NeoGenomics (NASDAQ:NEO) last posted its earnings results on Tuesday, July 26th. The company reported $0.04 EPS for the quarter, beating the consensus estimate of $0.03 by $0.01. The firm earned $63.10 million during the quarter, compared to the consensus estimate of $61.07 million. NeoGenomics had a positive return on equity of 3.18% and a negative net margin of 3.76%. The business’s quarterly revenue was up 159.0% on a year-over-year basis. During the same period last year, the company earned $0.01 earnings per share. Equities research analysts anticipate that NeoGenomics will post $0.13 EPS for the current year.
In related news, insider Maher Albitar sold 60,075 shares of the firm’s stock in a transaction that occurred on Monday, September 12th. The stock was sold at an average price of $8.23, for a total transaction of $494,417.25. Following the completion of the sale, the insider now owns 165,375 shares of the company’s stock, valued at $1,361,036.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 12.20% of the stock is owned by insiders.
Large investors have recently added to or reduced their stakes in the company. State Street Corp boosted its stake in NeoGenomics by 0.9% in the first quarter. State Street Corp now owns 777,559 shares of the company’s stock valued at $5,241,000 after buying an additional 7,266 shares in the last quarter. Falcon Point Capital LLC boosted its stake in NeoGenomics by 12.5% in the second quarter. Falcon Point Capital LLC now owns 209,538 shares of the company’s stock valued at $1,685,000 after buying an additional 23,216 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. boosted its stake in NeoGenomics by 14,127.6% in the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 142,276 shares of the company’s stock valued at $959,000 after buying an additional 141,276 shares in the last quarter. Fox Run Management L.L.C. acquired a new stake in NeoGenomics during the second quarter valued at approximately $171,000. Finally, Geode Capital Management LLC boosted its stake in NeoGenomics by 3.8% in the first quarter. Geode Capital Management LLC now owns 355,158 shares of the company’s stock valued at $2,393,000 after buying an additional 13,052 shares in the last quarter. 77.20% of the stock is owned by institutional investors and hedge funds.
Receive News & Stock Ratings for NeoGenomics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics Inc. and related stocks with our FREE daily email newsletter.